• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伏格特-小柳-原田病的预后因素

Prognostic factors in Vogt-Koyanagi-Harada disease.

作者信息

Al-Kharashi Abdullah S, Aldibhi Hassan, Al-Fraykh Hamad, Kangave Dustan, Abu El-Asrar Ahmed M

机构信息

Department of Ophthalmology, College of Medicine, King Saud University, Riyadh 11411, Saudi Arabia.

出版信息

Int Ophthalmol. 2007 Apr-Jun;27(2-3):201-10. doi: 10.1007/s10792-007-9062-9. Epub 2007 Apr 14.

DOI:10.1007/s10792-007-9062-9
PMID:17435968
Abstract

PURPOSE

To identify prognostic factors for final visual outcome, development of complications, and recurrent inflammation in patients with Vogt-Koyanagi-Harada (VKH) disease.

METHODS

All patients diagnosed with acute uveitis associated with VKH disease at the King Khaled Eye Specialist Hospital and King Abdulaziz University Hospital between January 1999 and February 2004 were reviewed. Data collected included age, gender, initial and final visual acuities, clinical findings at presentation, interval between onset of disease and starting treatment, treatment received, complications, number of recurrences, extraocular manifestations, and duration of follow-up period.

RESULTS

Sixty-eight patients were identified. There were 51 (75%) females and 17 (25%) males with a mean age of 25.04 +/- 10.28 years (range 7-55 years). The mean follow-up period was 34.4 +/- 20.1 months (range 8-62 months). The following factors were significantly associated with final visual acuity of 20/20 by univariate analysis: good initial visual acuity of better than 20/200 (p = 0.0415), absence of posterior synechiae of the iris at presentation (p = 0.0106), use of systemic corticosteroids for longer than nine months (p = 0.0479), slow tapering of systemic corticosteroids (p = 0.0024), absence of complications (p < 0.001), and absence of extraocular manifestations (p = 0.0124). Logistic regression analysis identified the use of systemic corticosteroids for longer than nine months to be associated with final visual acuity of 20/20 [odds ratio = 3.4; 95% confidence interval (CI) = 1.14-10.1]. The following factors were significantly associated with the development of complications by univariate analysis: age older than 18 years (p = 0.0161), initial visual acuity of 20/200 or worse (p = 0.0011), and presence of posterior synechiae of the iris at presentation (p = 0.0453). Factors identified after logistic regression analyses were age older than 18 years (odds ratio = 3.3; 95% CI = 1.33-8.17), and presence of posterior synechiae of the iris at presentation (odds ratio = 3.42; 9% CI = 1.38-8.47). Initial visual acuity of better than 20/200 was significantly associated with a lower risk of developing complications (odds ratio = 0.283; 95% CI = 0.129-0.629). The following factors were significantly associated with recurrent inflammation of three times or more by univariate analysis: initial visual acuity of 20/200 or worse (p = 0.0179), anterior chamber reaction of more than 2+ at presentation (p < 0.001), rapid tapering of systemic corticosteroids (p < 0.001), and development of extraocular manifestations (p = 0.0277).

CONCLUSIONS

Clinical findings at presentation, duration and method of tapering of systemic corticosteroids, and development of extraocular manifestations are significantly associated with final visual acuity, development of ocular complications, and recurrent inflammation. The development of ocular complications was significantly associated with a worse final visual acuity.

摘要

目的

确定伏格特-小柳-原田(VKH)病患者最终视力结果、并发症发生情况及炎症复发的预后因素。

方法

回顾了1999年1月至2004年2月在沙特国王哈立德眼科专科医院和阿卜杜勒阿齐兹国王大学医院诊断为与VKH病相关的急性葡萄膜炎的所有患者。收集的数据包括年龄、性别、初始和最终视力、就诊时的临床表现、疾病发作与开始治疗的间隔时间、接受的治疗、并发症、复发次数、眼外表现以及随访期的持续时间。

结果

共确定68例患者。其中女性51例(75%),男性17例(25%),平均年龄25.04±10.28岁(范围7 - 55岁)。平均随访期为34.4±20.1个月(范围8 - 62个月)。单因素分析显示,以下因素与最终视力达到20/20显著相关:初始视力优于20/200(p = 0.0415)、就诊时虹膜无后粘连(p = 0.0106)、全身使用皮质类固醇超过9个月(p = 0.0479)、全身皮质类固醇缓慢减量(p = 0.0024)、无并发症(p < 0.001)以及无眼外表现(p = 0.0124)。逻辑回归分析确定全身使用皮质类固醇超过9个月与最终视力达到20/20相关[比值比 = 3.4;95%置信区间(CI) = 1.14 - 10.1]。单因素分析显示,以下因素与并发症的发生显著相关:年龄大于18岁(p = 0.0161)、初始视力为20/200或更差(p = 0.0011)以及就诊时虹膜有后粘连(p = 0.0453)。逻辑回归分析后确定的因素为年龄大于18岁(比值比 = 3.3;95% CI = 1.33 - 8.17)以及就诊时虹膜有后粘连(比值比 = 3.42;9% CI = 1.38 - 8.47)。初始视力优于20/200与并发症发生风险较低显著相关(比值比 = 0.283;95% CI = 0.129 - 0.629)。单因素分析显示以下因素与炎症复发三次或更多次显著相关:初始视力为20/200或更差(p = 0.0179)、就诊时前房反应超过2+(p < 0.001)、全身皮质类固醇快速减量(p < 0.001)以及出现眼外表现(p = 0.0277)。

结论

就诊时的临床表现、全身皮质类固醇的使用时间和减量方法以及眼外表现的出现与最终视力、眼部并发症的发生以及炎症复发显著相关。眼部并发症的发生与更差的最终视力显著相关。

相似文献

1
Prognostic factors in Vogt-Koyanagi-Harada disease.伏格特-小柳-原田病的预后因素
Int Ophthalmol. 2007 Apr-Jun;27(2-3):201-10. doi: 10.1007/s10792-007-9062-9. Epub 2007 Apr 14.
2
Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.大剂量皮质类固醇治疗 Vogt-Koyanagi-Harada 病患者的临床转归的预后因素。
Acta Ophthalmol. 2013 Sep;91(6):e486-93. doi: 10.1111/aos.12127. Epub 2013 Apr 10.
3
Vogt-Koyanagi-Harada disease in children.儿童伏格特-小柳-原田病
Eye (Lond). 2008 Sep;22(9):1124-31. doi: 10.1038/sj.eye.6702859. Epub 2007 May 4.
4
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.霉酚酸酯联合全身用糖皮质激素可预防与Vogt-小柳-原田病相关的初发性急性葡萄膜炎进展为慢性复发性炎症和“晚霞眼底”的形成。
Acta Ophthalmol. 2017 Feb;95(1):85-90. doi: 10.1111/aos.13189. Epub 2016 Aug 18.
5
Complications and prognostic factors in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病的并发症及预后因素
Am J Ophthalmol. 2001 May;131(5):599-606. doi: 10.1016/s0002-9394(01)00937-0.
6
Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.预测因素与阿达木单抗治疗慢性复发性 Vogt-Koyanagi-Harada 病的疗效。
BMC Ophthalmol. 2024 Jun 7;24(1):238. doi: 10.1186/s12886-024-03511-9.
7
Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.慢性复发性伏格特-小柳-原田病及“晚霞样眼底”的出现预示视网膜敏感性更差。
Ocul Immunol Inflamm. 2017 Aug;25(4):475-485. doi: 10.3109/09273948.2016.1139730. Epub 2016 Mar 22.
8
A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.一例三岁女童疑诊 Vogt-Koyanagi-Harada 病。
BMC Ophthalmol. 2019 Aug 13;19(1):179. doi: 10.1186/s12886-019-1192-0.
9
Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.中国患者交感性眼炎与 Vogt-小柳原田病的临床特征和视力预后比较。
Ophthalmology. 2019 Sep;126(9):1297-1305. doi: 10.1016/j.ophtha.2019.03.049. Epub 2019 Apr 6.
10
Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.111 例新发急性 Vogt-小柳原田病患者采用脉冲静脉内皮质类固醇治疗的临床特征和视力结果。
Br J Ophthalmol. 2019 Feb;103(2):274-278. doi: 10.1136/bjophthalmol-2017-311691. Epub 2018 Apr 17.

引用本文的文献

1
Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population.硫唑嘌呤作为印度人群新发急性Vogt-小柳-原田病一线治疗的疗效。
Saudi J Ophthalmol. 2025 Feb 21;39(1):65-70. doi: 10.4103/sjopt.sjopt_200_23. eCollection 2025 Jan-Mar.
2
Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.预测因素与阿达木单抗治疗慢性复发性 Vogt-Koyanagi-Harada 病的疗效。
BMC Ophthalmol. 2024 Jun 7;24(1):238. doi: 10.1186/s12886-024-03511-9.
3
Vogt-Koyanagi-Harada Disease and COVID.

本文引用的文献

1
Chemokines and gelatinases in the aqueous humor of patients with active uveitis.活动性葡萄膜炎患者房水中的趋化因子和明胶酶
Am J Ophthalmol. 2004 Sep;138(3):401-11. doi: 10.1016/j.ajo.2004.04.046.
2
Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.伏格特-小柳-原田病伴或不伴慢性眼部炎症时的晚霞状眼底。
Graefes Arch Clin Exp Ophthalmol. 2002 Oct;240(10):878-82. doi: 10.1007/s00417-002-0538-z. Epub 2002 Sep 6.
3
Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease.
伏格特-小柳-原田病与新冠病毒
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
4
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients.儿童患者非感染性葡萄膜炎的诊断与治疗。
Paediatr Drugs. 2024 Jan;26(1):31-47. doi: 10.1007/s40272-023-00596-5. Epub 2023 Oct 4.
5
Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.Vogt-小柳-原田病的治疗与预后:长期随访的实际经验
J Clin Med. 2022 Jun 23;11(13):3632. doi: 10.3390/jcm11133632.
6
High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada 病中闭角型青光眼的高发率。
Int Ophthalmol. 2022 Dec;42(12):3913-3921. doi: 10.1007/s10792-022-02412-4. Epub 2022 Jul 5.
7
Phacoemulsification after trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease: intermediate-term visual outcome, IOP control and trabeculectomy survival.虹睫炎相关性 Vogt-小柳原田病患者行小梁切除术联合超声乳化白内障吸除术后的中期临床效果、眼压控制及小梁切除术存活率。
BMC Ophthalmol. 2022 May 9;22(1):210. doi: 10.1186/s12886-022-02438-3.
8
Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome.Vogt-小柳-原田综合征具有独特的临床谱及鉴别诊断特征。
BMJ Case Rep. 2019 Dec 29;12(12):e231397. doi: 10.1136/bcr-2019-231397.
9
Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.在初发性Vogt-小柳-原田葡萄膜炎早期抓住治疗时机可治愈该病。
Int Ophthalmol. 2019 Jun;39(6):1419-1425. doi: 10.1007/s10792-018-0949-4. Epub 2018 Jun 11.
10
Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病视网膜下纤维化的纵向观察
BMC Ophthalmol. 2018 Jan 15;18(1):6. doi: 10.1186/s12886-018-0670-0.
Vogt-小柳原田病中自身反应性T细胞的鉴定。
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2004-9.
4
Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease.交感性眼炎中的细胞因子产生与辅助性T细胞亚群
Curr Eye Res. 2001 Apr;22(4):312-8. doi: 10.1076/ceyr.22.4.312.5510.
5
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.Vogt-小柳-原田病修订诊断标准:国际命名委员会报告
Am J Ophthalmol. 2001 May;131(5):647-52. doi: 10.1016/s0002-9394(01)00925-4.
6
Complications and prognostic factors in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病的并发症及预后因素
Am J Ophthalmol. 2001 May;131(5):599-606. doi: 10.1016/s0002-9394(01)00937-0.
7
Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.酪氨酸酶家族蛋白是小柳原田病特有的抗原。
J Immunol. 2000 Dec 15;165(12):7323-9. doi: 10.4049/jimmunol.165.12.7323.
8
Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats.在Lewis大鼠中,酪氨酸酶相关蛋白1和2免疫诱导的眼内和眼外炎症。
Exp Eye Res. 2000 Oct;71(4):361-9. doi: 10.1006/exer.2000.0893.
9
Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病患者的视网膜下纤维化
Ophthalmology. 2000 Sep;107(9):1721-8. doi: 10.1016/s0161-6420(00)00244-x.
10
Extensive chorioretinal atrophy in Vogt-Koyanagi-Harada disease.伏格特-小柳-原田病中的广泛脉络膜视网膜萎缩。
Jpn J Ophthalmol. 1999 Mar-Apr;43(2):113-9. doi: 10.1016/s0021-5155(98)00066-5.